Patent Granted for MoAbs Used in Neoprobe's RIGScan Products

DUBLIN, Ohio--Neoprobe Corporation has announced that a patentgranted to Jeffrey Schlom, PhD, of the National Cancer Institute,and David Colcher, PhD, of the University of Nebraska MedicalCenter, covers claims to composition of matter for a large groupof second-generation monoclonal antibodies that target the tumor-associatedantigen TAG-72.

Neoprobe holds an exclusive global license for use of these antibodieswith its RIGS technology for surgical detection and treatmentof cancer. The antibodies named in the patent include CC49, acomponent of Neo-probe's first commercial product, RIGScan CR49,currently under investigation for colorectal cancer.